Skip to main content
. Author manuscript; available in PMC: 2020 Mar 12.
Published in final edited form as: J Bone Miner Res. 2019 Oct 14;35(1):196–210. doi: 10.1002/jbmr.3876

Figure 8. Inhibition of YAP/TAZ-TEAD with verteporfin (VP) reduced TGF-β-induced PLR gene expression in vitro.

Figure 8.

A) Osteocyte-like IDG-SW3 cells were differentiated for 21 days, with osteocyte differentiation reported by DMP1-GFP transgene expression. Cells were combinatorially treated with inhibitor verteporfin (VP) and/or 5 ng/ml TGFβ1 at day 21. B-G) mRNA expression, normalized to 18S rRNA, was evaluated for (B) serpin family E member 1 (SerpinE1), (C) cysteine-rich angiogenic inducer 61 (Cyr61), (D) connective tissue growth factor (Ctgf), (E) cathepsin K (Ctsk), (F) matrix metalloproteinase-13 (Mmp13), and (G) matrix metalloproteinase-14 (Mmp14). Relative expression was expressed as fold vs. vehicle (PBS + DMSO)-treated cells. Data are presented with individual samples in scatterplots and bars corresponding to the mean and standard error of the mean (SEM). Sample sizes, N = 3. Scale bars equal 75 mm.